Alpa Laboratories' Q3 FY 2025-26 Quarterly Results
- 12 Feb 2026
Result Summary
- Alpa Laboratories Ltd reported a 2.2% quarter-on-quarter (QoQ) increase in its consolidated revenues for the quarter-ended Dec (Q3 FY 2025-26). On a year-on-year (YoY) basis, it witnessed a decline of 14.3%.
- Its expenses for the quarter were down by 3.4% QoQ and up 8.3% YoY.
- The net profit increased 1627.3% QoQ and decreased 78.7% YoY.
- The earnings per share (EPS) of Alpa Laboratories Ltd stood at 0.9 during Q3 FY 2025-26.
Financial Statments for Q3 FY 2025-26
Total Income | 29.96 | 29.32 | 34.95 | 2.2% | -14.3% |
Total Expenses | 28.22 | 29.20 | 26.05 | -3.4% | 8.3% |
Profit Before Tax | 1.75 | 0.11 | 8.90 | 1490.9% | -80.3% |
Tax | -0.16 | 0.00 | 0.00 | - | - |
Profit After Tax | 1.90 | 0.11 | 8.90 | 1627.3% | -78.7% |
Earnings Per Share | 0.90 | 0.05 | 4.23 | 1700.0% | -78.7% |
Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results
Company Overview
Alpa Laboratories Ltd is a company engaged in the pharmaceutical industry, primarily involved in the production and distribution of various pharmaceuticals and healthcare products. The company specializes in manufacturing formulations in the form of tablets, capsules, injections, ointments, and others. Alpa Laboratories has made significant strides in developing a range of products catering to different therapeutic categories. As of the information available, there are no major developments or recent changes in the company's operations or market approach. The company operates in a competitive industry that is subject to regulatory changes and market dynamics.
Revenue
In the third quarter of the fiscal year 2026 (Q3FY26), Alpa Laboratories Ltd reported a total income of ₹29.96 crores. This reflects a quarter-over-quarter (QoQ) increase of 2.2% from ₹29.32 crores in Q2FY26. However, when compared to the same quarter in the previous year (Q3FY25), there was a year-over-year (YoY) decline of 14.3% from ₹34.95 crores. The revenue fluctuation could be indicative of changes in market demand or variations in sales across different products or regions.
Profitability
The profitability metrics for Alpa Laboratories Ltd demonstrate significant variations. The Profit Before Tax (PBT) for Q3FY26 was ₹1.75 crores, marking a substantial QoQ increase of 1490.9% from ₹0.11 crores in Q2FY26. However, this represents a YoY decrease of 80.3% from ₹8.90 crores in Q3FY25. The Profit After Tax (PAT) for the quarter was ₹1.90 crores, showing a remarkable QoQ increase of 1627.3% from ₹0.11 crores in Q2FY26, but a YoY decrease of 78.7% from ₹8.90 crores in Q3FY25. The Earnings Per Share (EPS) for Q3FY26 was ₹0.90, up 1700.0% QoQ from ₹0.05 in Q2FY26, yet down 78.7% YoY from ₹4.23 in Q3FY25. These figures highlight notable shifts in profitability over the periods in question.
Operating Metrics
The total expenses for Alpa Laboratories Ltd in Q3FY26 were reported at ₹28.22 crores, which is a decrease of 3.4% QoQ from ₹29.20 crores in Q2FY26. However, there was an 8.3% YoY increase from ₹26.05 crores in Q3FY25. The company's operating expenses management shows a reduction in costs from the previous quarter, although they have increased compared to the same quarter last year. The tax figures for Q3FY26 show a credit of ₹0.16 crores, whereas there were no taxes reported in both Q2FY26 and Q3FY25. This tax credit may have contributed to the net profitability for the quarter. The financial data does not provide information on key financial ratios or other operating metrics such as P/E ratio or debt-to-equity ratio, which are essential for a more comprehensive analysis.